A Phase 3 interventional study of Tolvaptan in Polycystic Kidney, Autosomal Dominant, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 210 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-27.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one has the largest enrollment, is one of 2 that started in 2014, is one of 8 in phase 3, and was the 11th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2014.
This study's enrollment of 1,803 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 91 across the 18 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 17 studies in Polycystic Kidney, Autosomal Dominant by Otsuka Holdings Co., Ltd., this one has the largest enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2014, is one of 7 in phase 3, and was the 12th registered.
Otsuka Holdings Co., Ltd.’s Polycystic Kidney, Autosomal Dominant studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Polycystic Kidney, Autosomal Dominant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).
This was a Phase 3b trial to evaluate and describe the long term safety of tolvaptan treatment in ADPKD participants with chronic kidney disease (CKD). Eligible participants could enroll into Trial 156-13-211 after completing the follow-up visit(s) of their previous trial (156-13-210, 156-08-271, 156-04-251, or 156-09-290). Renal function was assessed during screening by using historical laboratory values for serum creatinine levels to calculate the estimated glomerular filtration rate (eGFR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows: * Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability. * Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211. * Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.
Drug: Tolvaptan
Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Also known as: OPC-41061
Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was as any untoward medical occurrence associated with the use of an investigational medicinal product (IMP), whether or not considered IMP related. A TEAE was an AE that started after trial drug treatment; or if the event was continuous from baseline and was serious, related to IMP, or resulted in death, discontinuation, interruption or reduction of trial therapy. A serious TEAE included any event that resulted in: death, life-threatening, persistent or significant incapacity, substantial disruption of ability to conduct normal life functions, required inpatient hospitalization, prolonged hospitalization, congenital anomaly/birth defect, or other medically significant events as per medical judgment, that jeopardized the participant and that required medical or surgical intervention. A severe TEAE was an inability to work or perform normal daily activity. A summary of serious and all other non-serious TEAEs, regardless of causality, is located in the AE section.
Time frame: Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment(+ 7 days)
Eligible participants could enroll into Trial 156-13-211 after completing follow-up visit(s) of their previous trial (156-13-210, 156-08-271, 156-04-251, or 156-09-290).
| Milestone | Tolvaptan (From 156-13-210: Tolvaptan) | Tolvaptan (From 156-13-210: Placebo) | Tolvaptan (From 156-08-271: Tolvaptan) | Tolvaptan (From Other: Tolvaptan) | Tolvaptan (From Other: Placebo) |
|---|---|---|---|---|---|
| Started | 506 | 570 | 718 | 6 | 3 |
| Received at least 1 dose of study drug | 505 | 569 | 717 | 6 | 3 |
| Completed | 434 | 423 | 624 | 5 | 2 |
| Not completed | 72 | 147 | 94 | 1 | 1 |
| Withdrew: Adverse event | 23 | 60 | 28 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 6 | 4 | 0 | 0 |
| Withdrew: Physician decision | 19 | 30 | 26 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 25 | 51 | 35 | 1 | 0 |
An adverse event (AE) was as any untoward medical occurrence associated with the use of an investigational medicinal product (IMP), whether or not considered IMP related. A TEAE was an AE that started after trial drug treatment; or if the event was continuous from baseline and was serious, related to IMP, or resulted in death, discontinuation, interruption or reduction of trial therapy. A serious TEAE included any event that resulted in: death, life-threatening, persistent or significant incapacity, substantial disruption of ability to conduct normal life functions, required inpatient hospitalization, prolonged hospitalization, congenital anomaly/birth defect, or other medically significant events as per medical judgment, that jeopardized the participant and that required medical or surgical intervention. A severe TEAE was an inability to work or perform normal daily activity. A summary of serious and all other non-serious TEAEs, regardless of causality, is located in the AE section.
| participants | Tolvaptan (From 156-13-210: Tolvaptan) | Tolvaptan (From 156-13-210: Placebo) | Tolvaptan (From 156-08-271: Tolvaptan) | Tolvaptan (From Other: Tolvaptan) | Tolvaptan (From Other: Placebo) |
|---|---|---|---|---|---|
| Participants with TEAEs | 473 | 531 | 640 | 6 | 3 |
| Participants with serious TEAEs | 87 | 96 | 103 | 1 | 2 |
| Participants with severe TEAEs | 74 | 78 | 83 | 2 | 1 |
| Discontinued due to TEAEs | 33 | 65 | 38 | 0 | 1 |
| Deaths | 1 | 5 | 3 | 0 | 0 |
Collected over Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment (+ 7 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan (From 156-13-210: Tolvaptan) | 1/505 (0.2%) | 87/505 (17.2%) | 469/505 (92.9%) |
| Tolvaptan (From 156-13-210: Placebo) | 5/569 (0.9%) | 96/569 (16.9%) | 525/569 (92.3%) |
| Tolvaptan (From 156-08-271: Tolvaptan) | 3/717 (0.4%) | 103/717 (14.4%) | 633/717 (88.3%) |
| Tolvaptan (From Other: Tolvaptan) | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Tolvaptan (From Other: Placebo) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | Tolvaptan (From 156-13-210: Tolvaptan) | Tolvaptan (From 156-13-210: Placebo) | Tolvaptan (From 156-08-271: Tolvaptan) | Tolvaptan (From Other: Tolvaptan) | Tolvaptan (From Other: Placebo) |
|---|---|---|---|---|---|
| Ankle FractureInjury, poisoning and procedural complications | 1/505 | 0/569 | 1/717 | 0/6 | 1/3 |
| B-Cell Small Lymphocytic LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/505 | 0/569 | 0/717 | 0/6 | 1/3 |
| Hypertensive CrisisVascular disorders | 0/505 | 0/569 | 1/717 | 1/6 | 0/3 |
| Renal Cyst InfectionInfections and infestations | 5/505 | 8/569 | 1/717 | 0/6 | 0/3 |
| Acute Kidney InjuryRenal and urinary disorders | 5/505 | 8/569 | 7/717 | 0/6 | 0/3 |
| Renal ImpairmentRenal and urinary disorders | 6/505 | 2/569 | 3/717 | 0/6 | 0/3 |
| End Stage Renal DiseaseRenal and urinary disorders | 3/505 | 0/569 | 8/717 | 0/6 | 0/3 |
| PneumoniaInfections and infestations | 4/505 | 5/569 | 0/717 | 0/6 | 0/3 |
| Alanine Aminotransferase IncreasedInvestigations | 3/505 | 5/569 | 1/717 | 0/6 | 0/3 |
| Blood Creatinine IncreasedInvestigations | 1/505 | 5/569 | 3/717 | 0/6 | 0/3 |
| Event | Tolvaptan (From 156-13-210: Tolvaptan) | Tolvaptan (From 156-13-210: Placebo) | Tolvaptan (From 156-08-271: Tolvaptan) | Tolvaptan (From Other: Tolvaptan) | Tolvaptan (From Other: Placebo) |
|---|---|---|---|---|---|
| ThirstGeneral disorders | 139/505 | 183/569 | 91/717 | 4/6 | 0/3 |
| HaematuriaRenal and urinary disorders | 27/505 | 52/569 | 48/717 | 0/6 | 2/3 |
| Renal PainRenal and urinary disorders | 98/505 | 110/569 | 141/717 | 3/6 | 2/3 |
| HypertensionVascular disorders | 87/505 | 77/569 | 139/717 | 4/6 | 1/3 |
| Vulvovaginal Mycotic InfectionInfections and infestations | 3/234 | 1/290 | 6/343 | 0/5 | 1/2 |
| NocturiaRenal and urinary disorders | 77/505 | 124/569 | 58/717 | 3/6 | 1/3 |
| Vaginal HaemorrhageReproductive system and breast disorders | 0/234 | 1/290 | 3/343 | 0/5 | 1/2 |
| Motion SicknessEar and labyrinth disorders | 1/505 | 1/569 | 0/717 | 0/6 | 1/3 |
| Abdominal HerniaGastrointestinal disorders | 7/505 | 1/569 | 6/717 | 0/6 | 1/3 |
| ConstipationGastrointestinal disorders | 16/505 | 28/569 | 10/717 | 0/6 | 1/3 |
All participants who enrolled in the trial.
| Age, Continuous(Years) | Tolvaptan (From 156-13-210: Tolvaptan) | Tolvaptan (From 156-13-210: Placebo) | Tolvaptan (From 156-08-271: Tolvaptan) | Tolvaptan (From Other: Tolvaptan) | Tolvaptan (From Other: Placebo) | Total |
|---|---|---|---|---|---|---|
| Mean | 48.9 ± 8.1 | 48.6 ± 8.0 | 45.5 ± 7.8 | 41.2 ± 11.4 | 47.0 ± 2.6 | 47.4 ± 8.1 |
| Sex: Female, Male(Participants) | Tolvaptan (From 156-13-210: Tolvaptan) | Tolvaptan (From 156-13-210: Placebo) | Tolvaptan (From 156-08-271: Tolvaptan) | Tolvaptan (From Other: Tolvaptan) | Tolvaptan (From Other: Placebo) | Total |
|---|---|---|---|---|---|---|
| Female | 234 | 290 | 343 | 5 | 2 | 874 |
| Male | 272 | 280 | 375 | 1 | 1 | 929 |
| Ethnicity (NIH/OMB)(Participants) | Tolvaptan (From 156-13-210: Tolvaptan) | Tolvaptan (From 156-13-210: Placebo) | Tolvaptan (From 156-08-271: Tolvaptan) | Tolvaptan (From Other: Tolvaptan) | Tolvaptan (From Other: Placebo) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 27 | 25 | 49 | 1 | 0 | 102 |
| Not Hispanic or Latino | 479 | 545 | 669 | 5 | 3 | 1701 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tolvaptan (From 156-13-210: Tolvaptan) | Tolvaptan (From 156-13-210: Placebo) | Tolvaptan (From 156-08-271: Tolvaptan) | Tolvaptan (From Other: Tolvaptan) | Tolvaptan (From Other: Placebo) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 0 | 0 | 0 | 3 |
| Asian | 16 | 16 | 10 | 0 | 0 | 42 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 2 | 0 | 0 | 3 |
| Black or African American | 19 | 23 | 6 | 0 | 0 | 48 |
| White | 461 | 525 | 694 | 6 | 3 | 1689 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 6 | 6 | 0 | 0 | 18 |
Showing the first 100 of 210 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Ran from Oct 2014 to primary completion in Nov 2018, 48 months.
Results were first posted in Nov 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Polycystic Kidney, Autosomal Dominant →
Otsuka Pharmaceutical Development & Commercialization, Inc. →